What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock, with an average price target of $270.4, implying an upside from the current price of $186.46. The current average has increased by 34.08% from the previous average price target of $201.67.
May 31, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock, with an average price target of $270.4, implying an upside from the current price of $186.46.
The average price target of $270.4 for Alnylam Pharmaceuticals, as predicted by 10 analysts, implies an upside from the current price of $186.46. This indicates a positive short-term impact on the stock price, as the majority of analysts have a bullish or somewhat bullish outlook. The increase in the average price target by 34.08% from the previous average of $201.67 also supports this positive outlook.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100